161 related articles for article (PubMed ID: 20496201)
1. Analysis of time-to-event data under a two-stage survival adaptive design in clinical trials.
Lu Q; Tse SK; Chow SC
J Biopharm Stat; 2010 Jul; 20(4):705-19. PubMed ID: 20496201
[TBL] [Abstract][Full Text] [Related]
2. Analysis of time-to-event data with nonuniform patient entry and loss to follow-up under a two-stage seamless adaptive design with weibull distribution.
Lu Q; Tse SK; Chow SC; Lin M
J Biopharm Stat; 2012; 22(4):773-84. PubMed ID: 22651114
[TBL] [Abstract][Full Text] [Related]
3. Sample size estimation based on event data for a two-stage survival adaptive trial with different durations.
Lu Q; Chow SC; Tse SK; Chi Y; Yang LY
J Biopharm Stat; 2009; 19(2):311-23. PubMed ID: 19212882
[TBL] [Abstract][Full Text] [Related]
4. Statistical analysis for two-stage seamless design with different study endpoints.
Chow SC; Lu Q; Tse SK
J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
[TBL] [Abstract][Full Text] [Related]
5. Multiple-arm superiority and non-inferiority designs with various endpoints.
Chang M
Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
[TBL] [Abstract][Full Text] [Related]
6. Hierarchical testing of multiple endpoints in group-sequential trials.
Glimm E; Maurer W; Bretz F
Stat Med; 2010 Jan; 29(2):219-28. PubMed ID: 19827011
[TBL] [Abstract][Full Text] [Related]
7. Testing for qualitative interactions between stages in an adaptive study.
Parker RA
Stat Med; 2010 Jan; 29(2):210-8. PubMed ID: 19908261
[TBL] [Abstract][Full Text] [Related]
8. Non-parametric assessment of non-inferiority with censored data.
Freitag G; Lange S; Munk A
Stat Med; 2006 Apr; 25(7):1201-17. PubMed ID: 16345041
[TBL] [Abstract][Full Text] [Related]
9. A note on sample size calculation for mean comparisons based on noncentral t-statistics.
Chow SC; Shao J; Wang H
J Biopharm Stat; 2002 Nov; 12(4):441-56. PubMed ID: 12477068
[TBL] [Abstract][Full Text] [Related]
10. On Two-stage Seamless Adaptive Design in Clinical Trials.
Chow SC; Tu YH
J Formos Med Assoc; 2008 Dec; 107(12 Suppl):52-60. PubMed ID: 19129046
[TBL] [Abstract][Full Text] [Related]
11. Many-to-one comparison after sample size reestimation for trials with multiple treatment arms and treatment selection.
Wang J
J Biopharm Stat; 2010 Sep; 20(5):927-40. PubMed ID: 20721782
[TBL] [Abstract][Full Text] [Related]
12. Choice of delta noninferiority margin and dependency of the noninferiority trials.
Tsong Y; Zhang J; Levenson M
J Biopharm Stat; 2007; 17(2):279-88. PubMed ID: 17365224
[TBL] [Abstract][Full Text] [Related]
13. A note on P-values under group sequential testing and nonproportional hazards.
Gillen DL; Emerson SS
Biometrics; 2005 Jun; 61(2):546-51. PubMed ID: 16011703
[TBL] [Abstract][Full Text] [Related]
14. Mixed noninferiority margin and statistical tests in active controlled trials.
Tsou HH; Hsiao CF; Chow SC; Yue L; Xu Y; Lee S
J Biopharm Stat; 2007; 17(2):339-57. PubMed ID: 17365228
[TBL] [Abstract][Full Text] [Related]
15. Phase II cancer clinical trials with a one-sample log-rank test and its corrections based on the Edgeworth expansion.
Sun X; Peng P; Tu D
Contemp Clin Trials; 2011 Jan; 32(1):108-13. PubMed ID: 20888929
[TBL] [Abstract][Full Text] [Related]
16. A seamless phase II/III design with sample-size re-estimation.
Bischoff W; Miller F
J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
[TBL] [Abstract][Full Text] [Related]
17. The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.
Mielke M; Munk A; Schacht A
Stat Med; 2008 Nov; 27(25):5093-110. PubMed ID: 18570271
[TBL] [Abstract][Full Text] [Related]
18. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
Lui KJ; Chang KC
Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
[TBL] [Abstract][Full Text] [Related]
19. Sample sizes for clinical trials with time-to-event endpoints and competing risks.
Schulgen G; Olschewski M; Krane V; Wanner C; Ruf G; Schumacher M
Contemp Clin Trials; 2005 Jun; 26(3):386-96. PubMed ID: 15911472
[TBL] [Abstract][Full Text] [Related]
20. Interim futility analysis with intermediate endpoints.
Goldman B; LeBlanc M; Crowley J
Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
